Treats hypertension. Sold as Edarbi. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 16, 2026, FDA lists 2 applications for Azilsartan Kamedoxomil (sold as Edarbi), first approved Feb 25, 2011, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)Hypertension · Gedeon Richter Plc. | Phase 1 | Not yet recruiting | May 25, 2025 |
| Feb 25, 2011 | EdarbiNDA 200796 · New molecular entity | Azurity | 10 | Marketed |
| Jul 20, 2022 | Azilsartan MedoxomilANDA 214489 | Lupin | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA